title: Tumor necrosis factor superfamily member LIGHT induces epithelial-mesenchymal transition in A549 human alveolar epithelial cells.
abstract: Fibrosis is an abnormal response to organ injury, characterized by accumulation of activated fibroblasts at the sites of injury. Fibroblasts arise from several sources, including resident fibroblasts and circulating fibrocytes that infiltrate organ tissue. Recently, epithelial-mesenchymal transition (EMT) has been recognized as a source of mesenchymal cells. EMT is induced by various growth factors, such as transforming growth factor (TGF)-β1, and enhanced by inflammatory cytokines. Recently the tumor necrosis factor superfamily member LIGHT has been implicated in the pathogenesis of inflammatory disease and airway remodeling in severe asthma. We hypothesized that LIGHT might contribute to the pathogenesis of airway fibrosis via enhancement of EMT. Therefore, we investigated LIGHT's ability to induce EMT. A549 cells were stimulated with LIGHT, TGF-β1 or both for 48h. To estimate EMT, we evaluated the expression of epithelial and mesenchymal markers using immunocytochemistry, Western blotting and quantitative RT-PCR. Signaling pathways for EMT were characterized by Western analysis to detect phosphorylation of Erk1/2 and smad2. LIGHT enhanced TGF-β1-induced EMT both morphologically, by suppressing E-cadherin and enhancing vimentin, and functionally, by enhancing cell contractility. Additionally, LIGHT induced EMT without TGF-β1. Evaluation of the mechanism showed that LIGHT did not induce TGF-β1 production or affect the smad-snai1 pathway. Inhibition of Erk1/2 phosphorylation reduced LIGHT-induced EMT, indicating the Erk1/2 pathway to be a key pathway in LIGHT-induced EMT. In summary, LIGHT enhanced TGF-β1-induced EMT but also induced EMT via the Erk1/2 pathway by itself, without TGF-β1 signaling. LIGHT may contribute to the pathogenesis of airway fibrosis through enhancement of EMT.
authors.affiliation: Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Mikami
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Horie
authors.forename: Makiko
authors.initials: M
authors.lastname: Kase
authors.forename: Taisuke
authors.initials: T
authors.lastname: Jo
authors.forename: Hajime
authors.initials: H
authors.lastname: Takizawa
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kohyama
authors.forename: Takahide
authors.initials: T
authors.lastname: Nagase
mesh_terms: D045744:Cell Line, Tumor; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects / Q000502:physiology*; D005355:Fibrosis; D006801:Humans; D020935:MAP Kinase Signaling System; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D020545:Respiratory Mucosa / Q000187:drug effects / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000494:pharmacology; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14 / Q000494:pharmacology / Q000502:physiology*
chemical_list: D016212:Transforming Growth Factor beta; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14